In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Axon Enterprise's current price exceeds its high-confidence fair value by 26.5%, indicating potential overvaluation despite a Monte Carlo analysis showing minimal downside risk. Valuations via DCF and earnings multiples are notably negative, contrasting sharply with bullish analyst targets skewing the weighted average. Strong liquidity and growth coexist with weak profitability and efficiency, increasing financial risk despite a good overall health score.